IP Verse

Methods For The Treatment Of Scleroderma

EP3860590

ARENA PHARMACEUTICALS, INC.
Application Number
EP19790404A
Filing Date
Oct 3, 2019
Status
Granted And Under Opposition
May 5, 2023
Grant Date
Jun 7, 2023
External Links
Slate, Register

Biblio Summary

The patent EP3860590B1 was granted on Jun 7, 2023 by Arena Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM&WITTKOPP PATENTANWALTE PARTMBBMar 7, 2024ADMISSIBLE
TEVAFeb 29, 2024ADMISSIBLE

More Opposed Patents of Arena Pharmaceuticals, Inc.

The table below shows the patents of Arena Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3310760Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated DisordersOct 19, 20222

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents